The overall risk for infection in patients with rheumatoid arthritis who are treated with nontumor necrosis factor inhibitors is highest among those treated with rituximab compared with abatacept and tocilizumab.
Elevated levels of certain serum sphingolipids collected from patients with rheumatoid arthritis (RA) suggest that they may play an important role in RA pathophysiology.
Routine Assessment of Patient Index Data 3, DAS28 (CRP) and modified DAS28 (CRP) are stronger predictors of structural damage progression than the Simplified or Clinical Disease Activity Indices.
In a real-world setting, tocilizumab was effective regardless of comorbidity burden or obesity in patients with rheumatoid arthritis.
Investigators sought to determine whether blocking the toll-like receptor 4 pathway alone does or does not improve disease parameters in patients with rheumatoid arthritis, a human immune-mediated inflammatory disease.